美国 · SEC FORM 4
FATE THERAPEUTICS INC
FATE · Nasdaq · CIK 0001434316 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
8 同一窗口内观察到的 Form 4 交易行
4 sales · 4 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2024-12-20 · Green Jeremy; Redmile Group, LLC.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 10,759,313
- 上期报告
- 9,386,451
- 日均成交量
- 2,041,291
- 回补天数
- 5.3
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2024-12-20 | Green Jeremy; Redmile Group, LLC | 买入 (P) | Common Stock | 397,964 | USD 1.68 | USD 668,580 | SEC 申报 ↗ |
| 2023-12-26 | Green Jeremy; Redmile Group, LLC | 买入 (P) | Common Stock | 44,630 | USD 3.72 | USD 166,024 | SEC 申报 ↗ |
| 2023-04-21 | Green Jeremy; Redmile Group, LLC | 买入 (P) | Common Stock | 256,639 | USD 6.18 | USD 1,586,029 | SEC 申报 ↗ |
| 2023-04-20 | Green Jeremy; Redmile Group, LLC | 买入 (P) | Common Stock | 20,000 | USD 5.99 | USD 119,800 | SEC 申报 ↗ |
| 2023-04-14 | Green Jeremy; Redmile Group, LLC | 买入 (P) | Common Stock | 25,700 | USD 6.00 | USD 154,200 | SEC 申报 ↗ |
| 2023-01-13 | MENDLEIN JOHN | 买入 (P) | Common Stock | 36,631 | USD 5.43 | USD 198,906 | SEC 申报 ↗ |
| 2023-01-11 | MENDLEIN JOHN | 买入 (P) | Common Stock | 88,048 | USD 5.67 | USD 499,232 | SEC 申报 ↗ |
| 2021-01-08 | Green Jeremy; Redmile Group, LLC | 买入 (P) | Common Stock | 327,485 | USD 85.50 | USD 27,999,968 | SEC 申报 ↗ |
| 2020-06-11 | Green Jeremy; Redmile Group, LLC | 买入 (P) | Common Stock | 1,412,928 | USD 28.31 | USD 39,999,992 | SEC 申报 ↗ |
Form 4 申报证据
15 transaction lines in the latest 365-day window; 393 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-04 | Valamehr Bahram | 卖出 (S) | Common Stock | 43,947 | USD 2.46 | USD 108,110 | SEC 申报 ↗ |
| 2026-08-04 | TAHL CINDY | 卖出 (S) | Common Stock | 38,800 | USD 2.46 | USD 95,448 | SEC 申报 ↗ |
| 2026-05-20 | Valamehr Bahram | 卖出 (S) | Common Stock | 28,946 | USD 1.88 | USD 54,418 | SEC 申报 ↗ |
展开近期 Form 4 证据 (14 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-04 | Valamehr Bahram | 卖出 (S) | Common Stock | 43,947 | USD 2.46 | USD 108,110 | SEC 申报 ↗ |
| 2026-08-04 | TAHL CINDY | 卖出 (S) | Common Stock | 38,800 | USD 2.46 | USD 95,448 | SEC 申报 ↗ |
| 2026-05-20 | Valamehr Bahram | 卖出 (S) | Common Stock | 28,946 | USD 1.88 | USD 54,418 | SEC 申报 ↗ |
| 2026-05-20 | TAHL CINDY | 卖出 (S) | Common Stock | 25,590 | USD 1.88 | USD 48,109 | SEC 申报 ↗ |
| 2026-05-06 | TAHL CINDY | 期权行权／转换 (M) | Common Stock | 166,664 | USD 1.25 | USD 207,997 | SEC 申报 ↗ |
| 2026-05-05 | RASTETTER WILLIAM H | 期权行权／转换 (M) | Common Stock | 25,000 | USD 1.69 | USD 42,250 | SEC 申报 ↗ |
| 2026-05-05 | EPSTEIN ROBERT S | 期权行权／转换 (M) | Common Stock | 25,000 | USD 1.69 | USD 42,250 | SEC 申报 ↗ |
| 2026-04-20 | Green Jeremy; RedCo II Master Fund, L.P.; Redmile Group, LLC | J (J) | Common Stock | 8,977,624 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-15 | Valamehr Bahram | 奖励／授予 (A) | Common Stock | 335,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-15 | TAHL CINDY | 奖励／授予 (A) | Common Stock | 100,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-15 | Adawi Kamal | 奖励／授予 (A) | Common Stock | 25,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-09 | Valamehr Bahram | 卖出 (S) | Common Stock | 5,190 | USD 1.07 | USD 5,553 | SEC 申报 ↗ |
| 2026-01-09 | TAHL CINDY | 卖出 (S) | Common Stock | 10,589 | USD 1.06 | USD 11,224 | SEC 申报 ↗ |
| 2025-10-20 | Adawi Kamal | 奖励／授予 (A) | Common Stock | 75,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | FATE |
| CIK | 0001434316 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 393 transaction lines from 2020-01-08 to 2026-08-04 9 P purchase lines · 254 S sale lines · 130 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.